Homer Adams - Concepedia

Author

Homer Adams

Also Known As

Fei Huang, H C Adams III, H. Adams, H. Adams III, Hailey K. Adams, Homer Adams, Homer Adams III, Homer C Adams, Homer C Adams III, Homer C. Adams

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Janssen (United States)Janssen (Belgium)Levine Cancer Institute Emory University Vejle Sygehus

About

Homer Adams is an author at Janssen (United States) specializing in immunodeficiencies, health sciences, and immune regulation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	1	1	42
2	Medicine	1	1	42
3	Immunology	1	1	42
4	Autoimmunity	1	1	42
5	Hematology	1	1	42

Homer Adams

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma Tineke Casneuf, Xu Steven Xu, Homer Adams, Blood Advances	2017	218
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action Homer Adams, Frederik Stevenaert, Jakub Krejcik, Cytometry Part A	2018	154
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma Christie P.M. Verkleij, Marloes E.C. Broekmans, Mark van Duin, Blood Advances	2021	153
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus Suzanne Cole, Alice M. Walsh, Xuefeng Yin, Arthritis Research & Therapy	2018	126
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab Tineke Casneuf, Homer Adams, Niels W.C.J. van de Donk, Leukemia	2020	111
Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia Adam J. Lamble, Yoko Kosaka, Ted Laderas, Proceedings of the National Academy of Sciences	2020	97
US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials Jeanne M. Regnante, Nicole Richie, Lola A. Fashoyin‐Aje, Journal of Oncology Practice	2019	93
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab Kristine A. Frerichs, Marloes E.C. Broekmans, Jhon A. Marin Soto, Clinical Cancer Research	2020	85
The Rho-specific Guanine Nucleotide Exchange Factor Dbs Regulates Breast Cancer Cell Migration Zhuoming Liu, Homer Adams, Ian P. Whitehead Journal of Biological Chemistry	2009	47
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM). Saad Z. Usmani, María‐Victoria Mateos, Hareth Nahi, Journal of Clinical Oncology ImmunodeficienciesImmunologyImmune RegulationImmunotherapeuticsCd3 Bispecific Antibody	2020	42

Page 1